Adenosine triphosphate/pH dual-responsive controlled drug release system with high cancer/normal cell selectivity and low side toxicity

Bo Fu; Hui-Chao Lin; Nian Chen; Ping Zhao

doi:10.1177/08853282221087412

Adenosine triphosphate/pH dual-responsive controlled drug release system with high cancer/normal cell selectivity and low side toxicity

J Biomater Appl. 2022 Aug;37(2):324-332. doi: 10.1177/08853282221087412. Epub 2022 Apr 15.

Authors

Bo Fu¹, Hui-Chao Lin², Nian Chen¹, Ping Zhao²

Affiliations

¹ College of Health Industry, Zhongshan Torch Polytechnic, Zhongshan, China.
² 71237School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Guangzhou, China.

PMID: 35428411
DOI: 10.1177/08853282221087412

Abstract

Most drug-delivery systems (DDS) suffer from poor selectivity to cancer/normal cells or the complicated synthetic process. Herein, we employed a novel facile method to develop an oligodeoxy nucleotides based DDS composed with adenosine-5^'- triphosphate (ATP) aptamer and a pH responsive cytosine (C) DNA fragment for specific daunomycine (DNM) delivery. The DDS has ATP/pH dual-responsive drug release, can selectively internalize into tumor cell lines and thus has ultrahigh cancer/normal cell selectivity over the individual drug. The non-chemical synthesis, controllable dual-responsive intracellular drug release, and high cancer/normal cell selectivity endowed the DDS high biocompatibility and significant tumor suppression.

Keywords: adenosine triphosphate/pH responsive; biosafety; cancer/normal selectivity; drug-delivery systems; tumor suppression.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adenosine Triphosphate
Cell Line, Tumor
Doxorubicin
Drug Delivery Systems
Drug Liberation
Hydrogen-Ion Concentration
Nanoparticles*
Neoplasms* / drug therapy
Pharmaceutical Preparations

Substances

Pharmaceutical Preparations
Doxorubicin
Adenosine Triphosphate